YONDELIS 1MG POLVO PARA CONCENTRADO EN SOLUCION POR INFUSION I.V. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

yondelis 1mg polvo para concentrado en solucion por infusion i.v.

asofarma s.a. - trabectedina - trabectedina....1mg

Trabectedin SUN 0,25 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung Germany - English - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

trabectedin sun 0,25 mg pulver für ein konzentrat zur herstellung einer infusionslösung

Trabectedin SUN 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung Germany - English - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

trabectedin sun 1 mg pulver für ein konzentrat zur herstellung einer infusionslösung

YONDELIS 0,25 mg vial pols Andorra - English - CedimCat (Centre d'Informació de Medicaments de Catalunya)

yondelis 0,25 mg vial pols

YONDELIS 1 mg vial pols Andorra - English - CedimCat (Centre d'Informació de Medicaments de Catalunya)

yondelis 1 mg vial pols

Trabectedine Teva 0,25 mg inj. sol. (pwdr., conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

trabectedine teva 0,25 mg inj. sol. (pwdr., conc.) i.v. vial

teva b.v. - trabectedin 0,25 mg - powder for concentrate for solution for infusion - 0,25 mg - trabectedin 0.25 mg - trabectedin

Trabectedine Teva 1 mg inj. sol. (pwdr., conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

trabectedine teva 1 mg inj. sol. (pwdr., conc.) i.v. vial

teva b.v. - trabectedin 1 mg - powder for concentrate for solution for infusion - 1 mg - trabectedin 1 mg - trabectedin

YONDELIS- trabectedin injection, powder, lyophilized, for solution United States - English - NLM (National Library of Medicine)

yondelis- trabectedin injection, powder, lyophilized, for solution

janssen products, lp - trabectedin (unii: id0yzq2tcp) (trabectedin - unii:id0yzq2tcp) - trabectedin 0.05 mg in 1 ml - yondelis® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see clinical studies (14)] . yondelis is contraindicated in patients with known severe hypersensitivity, including anaphylaxis, to trabectedin. risk summary based on its mechanism of action, trabectedin can cause fetal harm when administered during pregnancy [see clinical pharmacology (12.1)] . there are no available data with the use of yondelis during pregnancy. animal reproductive and developmental studies at relevant doses have not been conducted with trabectedin; however, placental transfer of trabectedin was demonstrated in pregnant rats. advise pregnant woman of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated population are unknown; however, the background risk in the u.s. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recog

YONDELIS 1 MG Israel - English - Ministry of Health

yondelis 1 mg

megapharm ltd - trabectedin - powder for concentrate for solution for injection - trabectedin 1 mg/vial - trabectedin - trabectedin - yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Trabectedine Sun 0.25 mg inj. sol. (pwdr., conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

trabectedine sun 0.25 mg inj. sol. (pwdr., conc.) i.v. vial

sun pharmaceutical industries europe b.v. - trabectedin 0,25 mg - powder for concentrate for solution for infusion - trabectedin